What is the FDA label indication for Cephalexin?

What is the FDA label indication for Cephalexin?

• A. Respiratory infections
• B. Skin and soft tissue infections
• C. Cardiovascular conditions
• D. Gastrointestinal disorders

Answer: (B)

Cephalexin is a first-generation cephalosporin antibiotic that has been specifically indicated for the treatment of various infections caused by susceptible bacteria. One of the primary labeled indications for Cephalexin is for the management of skin and soft tissue infections. These types of infections can include cellulitis, abscesses, and infections following minor surgical procedures or trauma, among others. Cephalexin is effective against bacteria that are commonly responsible for these infections, such as Staphylococcus aureus and Streptococcus pyogenes, making it a suitable choice for targeting infections in the skin and soft tissue. Its effectiveness in this area stems from its ability to disrupt bacterial cell wall synthesis, thus leading to cell lysis and death. While Cephalexin can also be utilized for other types of infections, such as respiratory infections, its primary FDA indication is indeed for skin and soft tissue infections, aligning with its spectrum of activity against the common pathogens that cause these conditions. This focus on bacterial pathogens associated with skin issues speaks to why this choice is the most accurate representation of its FDA label indication.

Cephalexin is a first-generation cephalosporin antibiotic that has been specifically indicated for the treatment of various infections caused by susceptible bacteria. One of the primary labeled indications for Cephalexin is for the management of skin and soft tissue infections. These types of infections can include cellulitis, abscesses, and infections following minor surgical procedures or trauma, among others.

Cephalexin is effective against bacteria that are commonly responsible for these infections, such as Staphylococcus aureus and Streptococcus pyogenes, making it a suitable choice for targeting infections in the skin and soft tissue. Its effectiveness in this area stems from its ability to disrupt bacterial cell wall synthesis, thus leading to cell lysis and death.

While Cephalexin can also be utilized for other types of infections, such as respiratory infections, its primary FDA indication is indeed for skin and soft tissue infections, aligning with its spectrum of activity against the common pathogens that cause these conditions. This focus on bacterial pathogens associated with skin issues speaks to why this choice is the most accurate representation of its FDA label indication.